Want to track ROIV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus. Genevant and Arbutus offer potential litigation value of $5-10 billion against Moderna and Pfizer.
Seekingalpha | 2 years ago
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25.
Zacks | 2 years ago
